CDK4 and neoplasm: The CDK4-specific effect of palbociclib on displacing p21 from cyclin D1-CDK4-p21—but not from cyclin D1-CDK6-p21—suggests that the relative ratio of CDK4 to CDK6 within a tumor may dictate drug sensitivity and resistance.